These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25155557)

  • 21. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.
    Pasqualetti F; Panichi M; Sainato A; Matteucci F; Galli L; Cocuzza P; Ferrazza P; Coraggio G; Pasqualetti G; Derosa L; Sollini M; Mannelli L; Ortori S; Monzani F; Ricci S; Greco C; Fabrini MG; Erba PA
    Radiat Oncol; 2016 Jan; 11():9. PubMed ID: 26796633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
    Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
    World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
    Battaglia A; Devos G; Decaestecker K; Witters M; Moris L; Van den Broeck T; Berghen C; Everaerts W; Albersen M; Tsaturyan A; De Meerleer G; Van Poppel H; Goffin K; Ost P; Tosco L; Joniau S
    World J Urol; 2019 Aug; 37(8):1543-1549. PubMed ID: 30859274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.
    Yan M; Moideen N; Bratti VF; Moraes FY
    Br J Radiol; 2020 Dec; 93(1116):20200496. PubMed ID: 32822547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial].
    Blanchard P; Foulon S; Louvel G; Habibian M; Fizazi K
    Cancer Radiother; 2017 Oct; 21(6-7):491-494. PubMed ID: 28869198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
    Koo KC; Dasgupta P
    Yonsei Med J; 2018 Jul; 59(5):567-579. PubMed ID: 29869454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
    Napieralska A; Miszczyk L; Stąpór-Fudzińska M
    Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligometastatic Prostate Cancer.
    Navrátil J; Poprach A; Lakomý R; Kocák I; Vašina J; Krupa P; Vyzula R
    Klin Onkol; 2019; 32(2):97-100. PubMed ID: 30995848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
    Supiot S; Rio E; Pacteau V; Mauboussin MH; Campion L; Pein F
    BMC Cancer; 2015 Sep; 15():646. PubMed ID: 26408012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
    Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
    World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.
    Markowski MC; Imus P; Wright JL; Schottenstein D; Paller CJ
    Clin Genitourin Cancer; 2017 Oct; 15(5):e839-e842. PubMed ID: 28325637
    [No Abstract]   [Full Text] [Related]  

  • 34. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
    Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
    Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic Radiotherapy for Oligometastasis.
    Otake S; Goto T
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30678111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience.
    Erie AJ; Morris JM; Welch BT; Kurup AN; Weisbrod AJ; Atwell TD; Schmit GD; Kwon ED; Callstrom MR
    J Vasc Interv Radiol; 2017 Jul; 28(7):987-992. PubMed ID: 28434661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer.
    Saxby H; Boussios S; Mikropoulos C
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Definitions of oligometastatic disease and new treatment concepts].
    Kissel M; Helou J; Thariat J
    Bull Cancer; 2018; 105(7-8):696-706. PubMed ID: 29935914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The role of radiotherapy to the primary tumor and metastases in patients with oligometastatic prostate cancer].
    Le Roy T; Baron D; Vandendorpe B; Bataille B; Hannoun-Levi JM; Blanchard P; Lartigau E; Latorzeff I; Pasquier D
    Cancer Radiother; 2021 Oct; 25(6-7):526-532. PubMed ID: 34400086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.